A major goal for cancer research is predicting which cancer cells will metastasise, and why, researchers said.
"The approach we've taken is a reverse approach from what is conventionally done," said Cynthia Reinhart-King, associate professor of biomedical engineering at Cornell university and senior author of the research.
"Instead of looking at what molecules are being expressed by the tumour, we're looking for the phenotype - that is, the behaviour - of individual cells first. Then we can determine what molecules are causing that behaviour," Reinhart-King said.
The problem is that it's easy to miss subtle differences in the tiny subpopulations of cells that are the most aggressive.
Taking, for example, 100 tumours and seeking out molecular biomarkers for metastasis, one particular molecule might be identified as being 'upregulated' in those tumours, Reinhart-King said.
But it's not the whole tumour expressing that particular molecule - some cells express the biomarker and some do not.
The researchers decided to first sort cells with the most aggressive behaviour, and analyse only them for molecular changes.
The researchers used the device to screen for cells with migratory responses to Epidermal Growth Factor, for which the receptor is known to be present in most human cancers and is tightly linked to poor prognosis.
"The thing we're most excited about, in addition to the physical device, is the conceptual framework we're using by trying to shift gears and screen for cells that are causing the worst parts of the disease," Reinhart-King said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
